COMP <GO>
LYEL vs LRMR // NET PROFIT MARGIN
Lyell Immunopharma Inc. (NASDAQ) VS. Larimar Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LYEL 2
— LRMR 1
■ METRIC PARITY
LAST: $11.31 (+3.43%) • MKT CAP: $277.0M
net-margins
-60.00%
LAST: $2.67 (+5.12%) • MKT CAP: $277.4M
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LYEL VS. LRMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LYEL | LRMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -41.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | LYEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.4 | 43.8 | +17.62 | LYEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $277.0M | $277.4M | -$336.8K | LRMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LYEL REV | LRMR REV | LYEL GROSS % | LRMR GROSS % | LYEL FCF | LRMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.0K | $0 | — | — | -$150.8M | -$113.3M |
| FY 2024 | $61.0K | $0 | — | — | -$162.9M | -$71.3M |
| FY 2023 | $130.0K | $0 | — | — | -$163.7M | -$33.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LYEL // BETA —
LRMR // BETA —